Photo of Laura M. Heiser, Ph.D.

Laura M. Heiser Ph.D.

  • (503) 346-4617
    • Associate Professor of Biomedical Engineering School of Medicine
    • Vice Chair Biomedical Engineering School of Medicine
    • OHSU Center for Spatial Systems Biomedicine

Dr. Heiser's research is focused on identifying pathways and aberrations associated with therapeutic response and resistance in cancer. In her studies, she uses an integrative systems biology approach to understand cancer as a complex system. Dr. Heiser is also an active member of the DREAM Consortium, which is a community-based effort to rigorously assess and advance algorithms in computational biology.

Education

  • B.A., University of California, Berkeley California 1998
  • Ph.D., University of Pittsburgh 2004

Publications

  • "Integrated analysis of breast cancer cell lines reveals unique signaling pathways" Genome Biology March 25 2009
  • "Analysis of molecular inversion probe performance for allele copy number determination" Genome Biology November 20 2007
  • "A community effort to assess and improve drug sensitivity prediction algorithms" Biotechnology December 1 2014
  • "Spatial updating in area LIP is independent of saccade direction" Journal of Neurophysiology May 2006
  • "A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047" BMC Medicine December 14 2009
  • "Dynamic circuitry for updating spatial representations. III. From neurons to behavior" Journal of Neurophysiology July 2007
  • "Dynamic circuitry for updating spatial representations. II. Physiological evidence for interhemispheric transfer in area LIP of the split-brain macaque" Journal of Neurophysiology November 2005
  • "Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with Anti-HER2 therapy" Clinical Cancer Research September 1 2015
  • "Metrics other than potency reveal systematic variation in responses to cancer drugs" Nature Chemical Biology November 2013
  • "ATM Suppresses SATB1-Induced Malignant Progression in Breast Epithelial Cells" PLoS One December 10 2012
  • "Corollary discharge and spatial updating" Progress in Brain Research  2005
  • "Modeling precision treatment of breast cancer." Genome Biology  2013
  • "Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase" Breast Cancer Research September 11 2014
  • "Bayesian Inference of Signaling Network Topology in a Cancer Cell Line" Bioinformatics November 2012
  • "Subtype and pathway specific responses to anticancer compounds in breast cancer" Proceedings of the National Academy of Sciences of the United States of America February 21 2012
  • "Spectral decomposition of signaling networks"   2007
  • "A Central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma" Cancer Discovery August 2012
  • "Dynamic circuitry for updating spatial representations. I. Behavioral evidence for interhemispheric transfer in the split-brain macaque" Journal of Neurophysiology November 2005
  • "Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition" Journal of Cancer Research January 15 2009
  • "Integrated genomic analyses of ovarian carcinoma" Nature June 30 2011
  • "A community computational challenge to predict the activity of pairs of compounds" Biotechnology December 1 2014
  • "Erratum to Modeling precision treatment of breast cancer [Genome Biology, 14, (2013), R110]" Genome Biology May 12 2015
  • "A robust prognostic signature for hormone-positive node-negative breast cancer" Genome Medicine October 11 2013
  • "Decoupling of the PI3K pathway via mutation necessitates combinatorial treatment in HER2+ breast cancer" PLoS One July 16 2015
  • "Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma" Oncotarget  2015
  • "Tumor-derived cell lines as molecular models of cancer pharmacogenomics" Molecular Cancer Research January 1 2016
  • "A network-based model of oncogenic collaboration for prediction of drug sensitivity" Frontiers in Genetics  2015
  • "Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer" Breast Cancer Research July 1 2016
  • "Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor" Oncotarget  2016
  • "Inferring causal molecular networks" Nature Methods March 30 2016

Additional information

Edit profile